News

Sunesis’ Aurora kinase inhibitors target cells in the mitotic phase of the cell cycle. In vivo results demonstrate robust activity, including significant tumor growth retardation, exceeding 80% in

Anthim is a therapeutic monoclonal antibody being developed by Elusys to prevent and treat anthrax infections. Following clearance of the investigational new drug (IND) by the FDA, Elusys

The principal purpose of the phase I clinical trial is to establish the safety of the VRX496 therapy in patients failing two or more HAART regimens. Each of

In its preliminary results statement of January 19 2005, GW announced that it would embark on a regulatory program in the US for its lead product, Sativex. The

The studies examined the anticoagulant and antiplatelet activities of MC-45308 in both in vitro and in vivo experiments. The anticoagulant effects of MC-45308 were evaluated with a series

Axcan received a three-year marketing exclusivity for the new dosage form under the non-patent exclusivity provisions of the Federal Food, Drug and Cosmetic Act. “The once-a-day Canasa 1,000mg

This clinical trial is an open-label dose escalation phase I/II study in which a single dose of Reolysin will be administered by infusion to patients with recurrent malignant

The companies are voluntarily suspending supply of Tysabri from commercial distribution and have requested that physicians stop prescribing the treatment. In addition, the companies have suspended dosing in

Under the amended agreement, Abbott will distribute and market Numax, MedImmune’s investigational second-generation anti-RSV (respiratory syncytial virus) monoclonal antibody (MAb) currently in phase III development, upon approval outside